These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17875580)

  • 1. History-adjusted marginal structural models for estimating time-varying effect modification.
    Petersen ML; Deeks SG; Martin JN; van der Laan MJ
    Am J Epidemiol; 2007 Nov; 166(9):985-93. PubMed ID: 17875580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect modification by time-varying covariates.
    Robins JM; Hernán MA; Rotnitzky A
    Am J Epidemiol; 2007 Nov; 166(9):994-1002; discussion 1003-4. PubMed ID: 17875581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures.
    Hernán MA; Brumback BA; Robins JM
    Stat Med; 2002 Jun; 21(12):1689-709. PubMed ID: 12111906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating causal treatment effects from longitudinal HIV natural history studies using marginal structural models.
    Ko H; Hogan JW; Mayer KH
    Biometrics; 2003 Mar; 59(1):152-62. PubMed ID: 12762452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Instrumental variables and inverse probability weighting for causal inference from longitudinal observational studies.
    Hogan JW; Lancaster T
    Stat Methods Med Res; 2004 Feb; 13(1):17-48. PubMed ID: 14746439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulating from marginal structural models with time-dependent confounding.
    Havercroft WG; Didelez V
    Stat Med; 2012 Dec; 31(30):4190-206. PubMed ID: 22826156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marginal structural models for estimating effect modification.
    Chiba Y; Azuma K; Okumura J
    Ann Epidemiol; 2009 May; 19(5):298-303. PubMed ID: 19362275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correcting for Measurement Error in Time-Varying Covariates in Marginal Structural Models.
    Kyle RP; Moodie EE; Klein MB; Abrahamowicz M
    Am J Epidemiol; 2016 Aug; 184(3):249-58. PubMed ID: 27416840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marginal Structural Models with Counterfactual Effect Modifiers.
    Zheng W; Luo Z; van der Laan MJ
    Int J Biostat; 2018 Jun; 14(1):. PubMed ID: 29883322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy.
    Seng R; Goujard C; Krastinova E; Miailhes P; Orr S; Molina JM; Saada M; Piroth L; Rouzioux C; Meyer L;
    AIDS; 2015 Mar; 29(5):595-607. PubMed ID: 25715104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures.
    Brumback BA; Hernán MA; Haneuse SJ; Robins JM
    Stat Med; 2004 Mar; 23(5):749-67. PubMed ID: 14981673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marginal Structural Models: unbiased estimation for longitudinal studies.
    Moodie EE; Stephens DA
    Int J Public Health; 2011 Feb; 56(1):117-9. PubMed ID: 20931349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation and prediction with HIV-treatment interruption data.
    Adams BM; Banks HT; Davidian M; Rosenberg ES
    Bull Math Biol; 2007 Feb; 69(2):563-84. PubMed ID: 17211735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical learning of origin-specific statically optimal individualized treatment rules.
    van der Laan MJ; Petersen ML
    Int J Biostat; 2007; 3(1):Article 6. PubMed ID: 19122792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural accelerated failure time models for survival analysis in studies with time-varying treatments.
    Hernán MA; Cole SR; Margolick J; Cohen M; Robins JM
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):477-91. PubMed ID: 15660442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doubly Robust and Efficient Estimation of Marginal Structural Models for the Hazard Function.
    Zheng W; Petersen M; van der Laan MJ
    Int J Biostat; 2016 May; 12(1):233-52. PubMed ID: 27227723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study.
    Jani IV; Sitoe NE; Alfai ER; Chongo PL; Quevedo JI; Rocha BM; Lehe JD; Peter TF
    Lancet; 2011 Oct; 378(9802):1572-9. PubMed ID: 21951656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Joint calibrated estimation of inverse probability of treatment and censoring weights for marginal structural models.
    Yiu S; Su L
    Biometrics; 2022 Mar; 78(1):115-127. PubMed ID: 33247594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
    Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
    Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.